CL2024002402A1 - Inhibidores de irak4 - Google Patents

Inhibidores de irak4

Info

Publication number
CL2024002402A1
CL2024002402A1 CL2024002402A CL2024002402A CL2024002402A1 CL 2024002402 A1 CL2024002402 A1 CL 2024002402A1 CL 2024002402 A CL2024002402 A CL 2024002402A CL 2024002402 A CL2024002402 A CL 2024002402A CL 2024002402 A1 CL2024002402 A1 CL 2024002402A1
Authority
CL
Chile
Prior art keywords
irak4 inhibitors
irak4
medicine
consequently
formula
Prior art date
Application number
CL2024002402A
Other languages
English (en)
Inventor
Terstiege Ina
Schiesser Stefan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2024002402A1 publication Critical patent/CL2024002402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se refiere a compuestos químicos de Fórmula (I), y sales farmacéuticamente aceptables de estos, que inhiben IRAK4 y en consecuencia tienen una posible utilidad en medicina.
CL2024002402A 2022-02-14 2024-08-12 Inhibidores de irak4 CL2024002402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263267956P 2022-02-14 2022-02-14

Publications (1)

Publication Number Publication Date
CL2024002402A1 true CL2024002402A1 (es) 2025-01-17

Family

ID=85227248

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002402A CL2024002402A1 (es) 2022-02-14 2024-08-12 Inhibidores de irak4

Country Status (18)

Country Link
US (2) US12240832B2 (es)
EP (1) EP4479137A1 (es)
JP (2) JP7555519B2 (es)
KR (1) KR20240051921A (es)
CN (1) CN118591536A (es)
AR (1) AR128506A1 (es)
AU (2) AU2023218575B2 (es)
CA (1) CA3250704A1 (es)
CL (1) CL2024002402A1 (es)
CO (1) CO2024012172A2 (es)
CR (1) CR20240383A (es)
DO (1) DOP2024000148A (es)
IL (1) IL314800A (es)
MX (1) MX2024009843A (es)
PE (1) PE20242100A1 (es)
TW (1) TW202400574A (es)
UY (1) UY40145A (es)
WO (1) WO2023152349A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326433A (en) 2023-08-11 2026-04-01 Astrazeneca Ab Crystalline irak4 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
WO2017207386A1 (de) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
CN114585609B (zh) 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途
KR20220027196A (ko) 2019-06-27 2022-03-07 바이오젠 엠에이 인코포레이티드 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
JP7353474B2 (ja) 2019-09-24 2023-09-29 上海美悦生物科技発展有限公司 Irak阻害剤、その製造方法及び用途
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
EP4267576A1 (en) 2020-12-22 2023-11-01 Biogen MA Inc. Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease
WO2022140415A1 (en) 2020-12-22 2022-06-30 Biogen Ma Inc. 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease
CA3224732A1 (en) * 2021-07-07 2023-01-12 Kevin M. Guckian Compounds for targeting degradation of irak4 proteins

Also Published As

Publication number Publication date
MX2024009843A (es) 2024-08-22
AU2023218575A1 (en) 2024-09-19
JP2024529501A (ja) 2024-08-06
AU2026203590A1 (en) 2026-05-28
CN118591536A (zh) 2024-09-03
CO2024012172A2 (es) 2024-09-30
US20240300923A1 (en) 2024-09-12
DOP2024000148A (es) 2024-09-15
US20250368613A1 (en) 2025-12-04
PE20242100A1 (es) 2024-10-28
EP4479137A1 (en) 2024-12-25
AR128506A1 (es) 2024-05-15
UY40145A (es) 2023-08-15
KR20240051921A (ko) 2024-04-22
AU2023218575B2 (en) 2026-06-18
CA3250704A1 (en) 2023-08-17
CR20240383A (es) 2024-11-22
TW202400574A (zh) 2024-01-01
JP2025020096A (ja) 2025-02-12
US12240832B2 (en) 2025-03-04
WO2023152349A1 (en) 2023-08-17
IL314800A (en) 2024-10-01
JP7555519B2 (ja) 2024-09-24

Similar Documents

Publication Publication Date Title
UY39561A (es) Inhibidores de IRAK4
CL2024002023A1 (es) Inhibidor del inflamosoma nlrp3 y uso del mismo
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
CO2024003923A2 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
MA33886B1 (fr) Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
CO2024012172A2 (es) Inhibidores de irak4
MA33364B1 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
UY30440A1 (es) Nuevos compuestos
MX2023014722A (es) Forma cristalina de tolebrutinib y método de preparación y su uso.
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
PE20130396A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
PE20110943A1 (es) Formulacion oral solida de alisquireno
MX2024002552A (es) Inhibidor del antigeno de membrana prostatica especifico y uso farmaceutico del mismo.
MX2025007935A (es) Nuevos inhibidores reversibles de dpp1 y usos de estos
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
PY2085970A (es) Compuestos químicos
CO2025002460A2 (es) Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos
JOP20250173A1 (ar) مثبط بروتين أرجينين مثيل ترانسفيراز 5-مثيل ثيوأدينوزين